Cargando…

Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?

Conventional cost-effectiveness analysis—i.e., assessing pharmaceuticals through a cost per quality-adjusted life year (QALY) framework—originated from a societal commitment to maximize population health given limited resources. This "extra-welfarist" approach has produced pricing and reim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Postma, Maarten J., Noone, Declan, Rozenbaum, Mark H., Carter, John A., Botteman, Marc F., Fenwick, Elisabeth, Garrison, Louis P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981887/ https://www.ncbi.nlm.nih.gov/pubmed/35382853 http://dx.doi.org/10.1186/s13023-022-02283-z

Ejemplares similares

What Is the Purpose of the Orphan Drug Act?
por: Herder, Matthew
Publicado: (2017)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
por: Medic, Goran, et al.
Publicado: (2017)

Estimating the clinical cost of drug development for orphan versus non-orphan drugs
por: Jayasundara, Kavisha, et al.
Publicado: (2019)

Disentangling the Cost of Orphan Drugs Marketed in the United States
por: Althobaiti, Hana, et al.
Publicado: (2023)

803 Direct Costs and Duration of Hospitalization of Patients Hospitalized with Community Acquired Pneumonia: a Nationwide Retrospective Claims Database Analysis
por: Rozenbaum, Mark, et al.
Publicado: (2014)

Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States
por: Bell, Christopher E., et al.
Publicado: (2003)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”
por: Tu, Hong Anh T, et al.
Publicado: (2013)

The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review
por: Vondeling, Gerard T., et al.
Publicado: (2018)

Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model
por: Rozenbaum, Mark H, et al.
Publicado: (2011)

Do investors value the FDA orphan drug designation?
por: Miller, Kathleen L.
Publicado: (2017)

Section 12 approval: fit for purpose?
por: Rigby, David, et al.
Publicado: (2019)

Section 12 approval: fit for purpose?
por: Gupta, Nidhi, et al.
Publicado: (2020)

Section 12 approval: fit for purpose?
por: Ballantyne-Watts, Darryl
Publicado: (2020)

Telemedicine: is the new normal fit for purpose?
por: The Lancet Rheumatology
Publicado: (2022)

Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world
por: Postma, Maarten J, et al.
Publicado: (2011)

The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
por: Kesselheim, Aaron S., et al.
Publicado: (2012)

Effectiveness, safety and costs of orphan drugs: an evidence-based review
por: Onakpoya, Igho J, et al.
Publicado: (2015)

Orphans in the Market: The History of Orphan Drug Policy
por: Mikami, Koichi
Publicado: (2019)

How to Value Orphan Drugs? A Review of European Value Assessment Frameworks
por: Blonda, Alessandra, et al.
Publicado: (2021)

Leadership of education psychological services: fit for purpose?
por: Booker, Roger
Publicado: (2013)

Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi
por: Hollis, Aidan
Publicado: (2019)

Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands
por: Hagendijk, Marije E., et al.
Publicado: (2021)

Principles for consistent value assessment and sustainable funding of orphan drugs in Europe
por: Gutierrez, Laura, et al.
Publicado: (2015)

Is Adding HCV Screening to the Antenatal National Screening Program in Amsterdam, The Netherlands, Cost-Effective?
por: Urbanus, Anouk T., et al.
Publicado: (2013)

Fit for purpose: perspectives on rapid reviews from end-user interviews
por: Hartling, Lisa, et al.
Publicado: (2017)

Readers of poly(ADP-ribose): designed to be fit for purpose
por: Teloni, Federico, et al.
Publicado: (2016)

Clinical trials in the pandemic age: What is fit for purpose?
por: Hartman, Dan, et al.
Publicado: (2020)

Conducting fit‐for‐purpose food safety risk assessments
por: Devos, Yann, et al.
Publicado: (2019)

Is the 10 g monofilament fit for purpose for diagnosing DPN?
por: Malik, Rayaz A
Publicado: (2023)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
por: Hendrickx, Kim, et al.
Publicado: (2021)

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs
por: Cummings, J, et al.
Publicado: (2010)

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
por: Garrison, Louis P., et al.
Publicado: (2020)

Relationship between bleeding episodes, health‐related quality of life and direct costs in adults with severe haemophilia A: Secondary analyses from the CHESS study
por: O'Hara, Jamie, et al.
Publicado: (2022)

Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs
por: Schey, C., et al.
Publicado: (2017)

The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products
por: Lee, Dawn, et al.
Publicado: (2022)

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
por: Pijeira Perez, Yankier, et al.
Publicado: (2023)

Rare diseases and orphan drugs: 500 years ago
por: Dooms, Marc M.
Publicado: (2015)

Expert validation of fit-for-purpose guidelines for designing programmes of assessment
por: Dijkstra, Joost, et al.
Publicado: (2012)

Margaret McCartney: The Care Quality Commission is not fit for purpose
por: McCartney, Margaret
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cqaoqh2r5nhecthgepn4mcslbt